Navigation Links
Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
Date:11/9/2010

SAN DIEGO, Nov. 9, 2010 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported highlights and financial results for its third quarter ended September 30, 2010.  Highlights of the quarter and recent developments include:

  • Website and market launch of Cardium's MedPodium product line, a portfolio of premium science-based, easy to use medicinals, neurologics, metabolics, nutraceuticals and aesthetics designed to promote and manage personal health.  The MedPodium product portfolio, which initially includes seven podiatry-focused advanced skin care products to promote foot health and comfort, are currently available MedPodium's web-based boutique at www.medpodium.com.  In the future, the Company plans to expand distribution and sell certain MedPodium products through various select distributors or retailers in the United States.
  • Planned addition of the new weight management product, Appexium™, to Cardium's MedPodium™ product line.  Appexium, a plant-derived non-prescription dietary supplement to be marketed under the trade name Linee™, is designed to facilitate healthy weight management.  Linee is expected to be launched and available for purchase at the MedPodium web boutique in mid-November.
  • Exclusive commercial development rights for certain novel supramacromolecular polymer complexes, which represent a potentially novel and practical way to integrate the use of Nitric Oxide into a variety of wound healing products, and that appear to be compatible with Cardium's Excellagen formulated collagen topical gel wound care dressing, which is currently the subject of a pending FDA 510(k) clearance application for marketing and sales in the United States.
  • New preclinical research findings demonstrating that the Company's Excellagen collagen woun
    '/>"/>

  • SOURCE Cardium Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
    2. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
    3. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
    4. Cardium Regains Listing Compliance With NYSE Amex
    5. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
    6. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
    7. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
    8. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
    9. Cardium Completes $6.0 Million Registered Direct Offering
    10. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
    11. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") ... science-based research and development, sales and marketing of ... announced today that it is awarding exclusive Vestiage ... of Reluma Skin Illuminating Facial Care. Qualified applicants ... sending an email to info(at)vestiageinc(dot)com and putting RELUMA ...
    (Date:5/23/2013)... -- BioScrip, Inc. (NASDAQ: BIOS ) today announced ... Global Healthcare Conference to be held June 3-6, 2013 ... Richard Smith , President and Chief Executive ... Financial Officer, will present on Monday, June 3, 2013 ... About BioScrip BioScrip, Inc. provides comprehensive infusion and ...
    (Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
    (Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
    Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
    ... 10 , - Abstracts 185 and 1112, ... announced results from,two randomized clinical studies presented at ... 44th Annual Meeting demonstrating that the,"basal plus" insulin ... daily (basal insulin) and APIDRA(R) once daily,(prandial insulin) ...
    ... HALO ), a biopharmaceutical company developing and,commercializing products ... at two investor conferences in September:, -- Merriman ... at the,Mark Hopkins InterContinental Hotel in San Francisco on ... p.m. Eastern Time); and, -- UBS,s 2008 Global ...
    ... today by the Tech Council of Maryland:, Maryland ... off but,it must be safeguarded and trouble looms., ... 21st century,economic engines we Marylanders can take heart and ... industry. This blossoming industry,has expanded over the years with ...
    Cached Biology Technology:Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 2Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 3Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 4Halozyme Therapeutics to Present at Upcoming Investor Conferences 2Protect Maryland's Bioscience Industry 2Protect Maryland's Bioscience Industry 3
    (Date:5/22/2013)... Md. (May 22, 2013)The omega 3 fatty acids in ... cardiovascular diseaseso much so that the American Heart Association ... a week, particularly fatty varieties rich in omega 3s. ... a mystery. In a new study, scientists led by ... on this phenomenon by providing evidence that fish oil ...
    (Date:5/22/2013)... can endanger the whole organism, as they may lead ... in Munich now report how byproducts of respiration cause ... DNA in our cells controls the form and function ... for this are encoded in the linear sequence of ... (A), cytosine (C), guanine (G) and thymine (T). Random ...
    (Date:5/22/2013)... for prostate cancer could become as easy for men ... UC Irvine research published today in the Journal ... than a decade of work, UC Irvine chemists have ... for prostate cancer in urine, meaning that the disease ... at dramatically lower cost. The same technology could potentially ...
    Breaking Biology News(10 mins):Fish oil may help the heart beat mental stress 2DNA damage: The dark side of respiration 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
    ... Ciona intestinalis , commonly known as the sea ... uncovered the origins of the second heart field in ... full genome has been sequenced--one that shares 80 percent ... clearly more primitive than creatures with backbones and spinal ...
    ... soil may get what they need by cultivating specific ... are exceptionally efficient at turning inorganic minerals into nutrients ... their findings in the July 2010 issue of the ... acidic forest soils, availability of inorganic nutrients is a ...
    ... than a bullet-proof vest yet synonymous with beauty and ... remarkable properties have yet to be fully replicated in ... properties as well as their looks, silk fibers have ... armor for 5,000 years. Silk spun by ...
    Cached Biology News:From the heart: How cells divide to form different but related muscle groups 2Some trees 'farm' bacteria to help supply nutrients 2Behind the secrets of silk lie high-tech opportunities 2
    No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
    5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
    Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
    ...
    Biology Products: